Zhejiang Hisun Pharmaceutical Co. Ltd. and Shanghai Aryl Pharmtech Co. Ltd. have disclosed bicyclic heteroaryl derivatives acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) allosteric inhibitors reported to be useful for the treatment of cancer, Noonan syndrome, LEOPARD syndrome, fibrosis, cardiovascular and immunological disorders.
Research led by Chalmers University of Technology and the Karolinska Institute in Sweden shows that glycosaminoglycans in the blood and urine can be used to detect 14 early-stage cancers.
At the ESMO Immuno-Oncology Congress 2022, Compugen Inc. shared phase I data for COM-701 in dual and triple combination with Bristol Meyers Squibb Co.’s Opdivo (nivolumab) and with or without BMS-986207. Compugen’s candidate demonstrated preliminary durable antitumor activity and immune activation in patients with platinum resistant ovarian cancer with a favorable safety and toxicity profile.
Vevo Therapeutics Inc. raised $12 million in an over-subscribed seed round to build out an in vivosingle-cell screening platform, which will enable it to interrogate simultaneously the effects of small molecule drug leads on multiple cancer cell lines.
New and updated clinical data presented by biopharma firms at the ESMO Immuno-Oncology Congress 2022, including: Immunocore, Jounce, NGM, Promontory, Rapt.
Shares of Oncopeptides AB dropped 35% Dec. 7 on the U.S. FDA’s request to withdraw marketing authorization of Pepaxto (melflufen), a drug that had gained accelerated approval in early 2021 for use in relapsed/refractory multiple myeloma. The move followed a negative advisory committee vote in September 2022 and is based on the outcome of the confirmatory phase III Ocean study.
Replimune Group Inc. has found consistent treatment efficacy in its pivotal phase II Ignyte melanoma study. The interim data strongly bolstered the stock (NASDAQ:REPL), which ended Dec. 7 with a 22% increase to $23.09. The new results for the combination treatment show what Replimune called clinically meaningful durable activity across the range of anti-PD1 failed cutaneous melanoma presentations, including in patients with moderate to high tumor burden, with 85% of responses ongoing.
Sinovent Inc. has divulged nitrogen-containing heterocyclic compounds acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
RSS
